Compass Therapeutics Shares Gain Ahead of Trial Data for Biliary Tract Cancer Drug

Dow Jones

Apr 25

By Kelly Cloonan

Shares of Compass Therapeutics rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer.

The stock gained 12% to $5.65 in after-hours trading on Friday. Through market close, shares are down 6.3% this year.

The clinical stage biopharmaceutical company said it would review topline secondary endpoints from the study on Monday at 8 a.m. ET. The trial assessed tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer.

The company has previously said that tovecimig is its lead asset. Chief Executive Thomas Schuetz said last month that upcoming data release for tovecimig could be transformational for the company.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

April 24, 2026 18:18 ET (22:18 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2630087873"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630087873\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630087873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-25 06:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630087873","market":"us","top_or_hot":-1,"title":"Compass Therapeutics Shares Gain Ahead of Trial Data for Biliary Tract Cancer Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer. \n</p>\n<p>\n  The stock gained 12% to $5.65 in after-hours trading on Friday. Through market close, shares are down 6.3% this year. \n</p>\n<p>\n  The clinical stage biopharmaceutical company said it would review topline secondary endpoints from the study on Monday at 8 a.m. ET. The trial assessed tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer. \n</p>\n<p>\n  The company has previously said that tovecimig is its lead asset. Chief Executive Thomas Schuetz said last month that upcoming data release for tovecimig could be transformational for the company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2026 18:18 ET (22:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Therapeutics Shares Gain Ahead of Trial Data for Biliary Tract Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Therapeutics Shares Gain Ahead of Trial Data for Biliary Tract Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-25 06:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer. \n</p>\n<p>\n  The stock gained 12% to $5.65 in after-hours trading on Friday. Through market close, shares are down 6.3% this year. \n</p>\n<p>\n  The clinical stage biopharmaceutical company said it would review topline secondary endpoints from the study on Monday at 8 a.m. ET. The trial assessed tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer. \n</p>\n<p>\n  The company has previously said that tovecimig is its lead asset. Chief Executive Thomas Schuetz said last month that upcoming data release for tovecimig could be transformational for the company. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 24, 2026 18:18 ET (22:18 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2630087873","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630087873","pubTimestamp":1777069080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Compass Therapeutics rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer.The stock gained 12% to $5.65 in after-hours trading on Friday. Through market close, shares are down 6.3% this year.The clinical stage biopharmaceutical company said it would review topline secondary endpoints from the study on Monday at 8 a.m. ET. The trial assessed tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer.The company has previously said that tovecimig is its lead asset. Chief Executive Thomas Schuetz said last month that upcoming data release for tovecimig could be transformational for the company.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CMPX":"Compass Therapeutics, Inc."},"translate_title":"Compass Therapeutics股价在胆道癌药物试验数据公布前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPX":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Compass Therapeutics rose after the company said it would host a webcast to review data from its Phase 2/3 study of a potential treatment for advanced biliary tract cancer. \n\n\n  The stock gained 12% to $5.65 in after-hours trading on Friday. Through market close, shares are down 6.3% this year. \n\n\n  The clinical stage biopharmaceutical company said it would review topline secondary endpoints from the study on Monday at 8 a.m. ET. The trial assessed tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer. \n\n\n  The company has previously said that tovecimig is its lead asset. Chief Executive Thomas Schuetz said last month that upcoming data release for tovecimig could be transformational for the company. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 24, 2026 18:18 ET (22:18 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}